Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells $1,466,250.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $58.65, for a total value of $1,466,250.00. Following the completion of the transaction, the chief executive officer owned 1,148,095 shares in the company, valued at $67,335,771.75. This represents a 2.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $57.04, for a total value of $1,426,000.00.
• On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $56.29, for a total value of $1,407,250.00.
• On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $41.50, for a total value of $1,037,500.00.
• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.10, for a total value of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total value of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total value of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total value of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $859,891.96.

Liquidia Trading Down 1.6%

Shares of NASDAQ:LQDA opened at $60.98 on Friday. Liquidia Corporation has a 12-month low of $11.85 and a 12-month high of $62.30. The business’s fifty day simple moving average is $42.06 and its 200-day simple moving average is $37.24. The company has a market capitalization of $5.42 billion, a PE ratio of 435.60 and a beta of 0.41. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia’s quarterly revenue was up 4187.1% compared to the same quarter last year. As a group, equities research analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on LQDA shares. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Oppenheimer raised their price objective on Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research report on Thursday, March 12th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and a consensus target price of $49.33.

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently modified their holdings of the stock. Segall Bryant & Hamill LLC acquired a new position in shares of Liquidia in the 1st quarter valued at about $2,111,000. Bank of America Corp DE lifted its holdings in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after buying an additional 360,372 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Liquidia by 25.0% in the 1st quarter. California State Teachers Retirement System now owns 72,438 shares of the company’s stock valued at $2,734,000 after buying an additional 14,485 shares during the period. Empowered Funds LLC acquired a new position in shares of Liquidia in the 1st quarter valued at about $3,650,000. Finally, Eversept Partners LP lifted its holdings in shares of Liquidia by 33.0% in the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after buying an additional 167,949 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).